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INTRODUCTION
Pleomorphic carcinoma of the lung (PCL) is a rare tumor,
which constitutes approximately 0.1-0.4% of all lung cancers,
and has a poor clinical outcome (1-3). Histologically PCLs
exhibit characteristic tumor components, i.e., malignant epi-
thelial and homologous sarcomatoid spindle/giant cells. The
recently updated WHO classification defined pleomorphic
carcinoma as ‘‘a poorly differentiated non-small cell carcino-
ma, namely, as a squamous cell carcinoma, adenocarcinoma
or large cell carcinoma, containing spindle cells and/or giant
cells, or as a carcinoma consisting only of spindle cells and
giant cells and added that the pleomorphic component should
comprise at least 10% of the neoplasm’’ (4). The co-expres-
sion of cytokeratin and vimentin is helpful in the diagnosis
of PCL (5-9). The immunoreactivity of epithelial and mes-
enchymal markers in PCL suggests that PCL is a malignant
neoplasm of epithelial origin (10-13). However, a variety of
morphologic features in PCL suggest the possibility that PCL
might be a heterogeneous group of tumors rather than an
epithelial cell-derived malignant tumor.
CD99 is a transmembrane protein encoded by the MIC-2
gene and is characteristically expressed in the Ewing family
of tumors/PNETs, a group of small cell tumors of childhood
and adolescence with a specific EWS/ETS gene rearrangement
(14-16). In addition, its expression also has been reported in
lymphoblastic lymphoma/leukemia and some epithelial tu-
mors (17-19). Recently CD99 was found to be a critical mo-
lecule that contributes to the regulation of apoptosis and the
cell cycle in malignant cells (20). Nevertheless, to the best of
our knowledge no study of the expression pattern and biolog-
ical role of CD99 has been undertaken in PCL. Thus, the aim
of this study was to evaluate the expression of CD99/MIC-2
protein in a series of PCLs and to investigate whether this
expression is related to morphological differentiation or prog-
nostic implications.
MATERIALS AND METHODS
Patients and samples
Formalin-fixed paraffin-embedded blocks of 21 cases of
pleomorphic carcinomas undergoing surgical resection (14
pneumonectomies, 7 lobectomies) between January 1, 1991
and July 30, 2002 were retrieved from the histopathology
files at Seoul National University Hospital and at Samsung
Medical Center, Seoul, Korea. Each tumor was reevaluated
with regard to staging and histologic types of tumor compo-
nent. Tumor staging was performed using the TNM classi-
fication system of the International Union Against Cancer.
Follow-up data were obtained from medical records. 
Immunohistochemistry
Tissue samples were processed using a heat-induced antigen
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Expression of CD99 in Pleomorphic Carcinomas of the Lung
Pleomorphic carcinoma of the lung (PCL) is characterized by a mixture of sarcoma-
toid and carcinoma components, and a poor prognosis. However, no immunophe-
notype of tumor markers has been characterized in PCL. To charaterize the immu-
nophenotype for CD99 in PCL, we performed an immunohistochemical evaluation
of PCLs for thyroid transcription factor-1 (TTF-1), cytokeratin (CK) 7 and 20, and for
CD99. CD99 was found to be expressed in both carcinomatous (47%) and sarco-
matous components such as spindle cells (92%) and giant cells (57%). In the case
of spindle cells, CK7 was expressed in 6 cases (46%) and TTF-1 in 2 cases (15%),
whereas for giant cells CK7 was expressed in 8 cases (57%) and TTF-1 in one case
(7%). However, CK20 was not expressed in either the carcinomatous or sarcoma-
tous components in any case. Thus, CD99 was found to be widely expressed in
both sarcomatous and carcinoma component in PCL. A clinicopathological analy-
sis showed no direct correlation between the expression of CD99 and the clinical
indices (stage, survival rate, invasion) of PCL.
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retrieval procedure and immunostained using the conventio-
nal streptavidin-ABC technique. Tissues were treated with
mouse monoclonal anti-CD99 antibody (clone YG32, Di-
NonA, Seoul, Korea) at a dilution of 1:250. Other antibodies
used were; anti-cytokeratin 7 (clone OV-TL 12/30, Dako,
Glostrup, Denmark; dilution 1:100), anti-EMA (clone E29,
Dako, Glostrup, Denmark; dilution 1:100), anti-vimentin
(clone V9, Dako, Glostrup, Denmark; dilution 1:50) and anti-
TTF-1 (clone 8G7G3/1, Dako, Glostrup, Denmark; dilution
1:100). As a negative control, primary antibodies were replac-
ed by irrelevant isotype-matched antibodies. Samples were
determined as immunoreactive for CD99 if cell membrane
staining or granular intracytoplasmic dotting was observed,
for TTF-1 if nuclear staining was present, and for the other
if cytoplasmic staining was observed. Tissues were deemed as
negative if staining was either completely absent or observed
in less than 10% of neoplastic cells.
Statistical analysis
Correlations between immunohistochemical profiles and
the patients’ clinical and pathological characteristics were
analyzed using the chi-square test or Fisher’s exact test (2-
sided) using SPSS version 10.0. pvalues for p<0.05 were taken
to be statistically significant.
RESULTS
Clinical findings
As summarized in Table 1, a total of 21 patients were in-
cluded in the study. They included 20 men and 1 woman and
ranged in age from 50 to 91 yr at the time of surgery (mean
age 65 yr). A large number of patients had a tumor onset age
of >60 yr (12 patients, 57.1%). Pathological staging was per-
formed according to the TNM classification of the Interna-
tional Union Against Cancer. Of the 21 patients, 3 patients
were at Stage IIA, 9 patients at Stage IIB, 6 patients at Stage
IIIA, and 3 patients at Stage IIIB. Follow-up of these patients
revealed that 12 patients (57.1%) died of PCL.
Pathologic and immunohistochemical findings
Microscopically, 15 cases contained non-small cell carcino-
ma combined with sarcomatous components, whereas 6 cases
showed only sarcomatous areas without evidence of carcino-
ma. The carcinomas in these 15 cases were large cell carcino-
ma in 8 cases, adenocarcinoma in 4, and squamous cell carci-
noma in 3. All 21 cases contained spindle cells or giant cells
or a mixture of these cell types (Fig. 1A, B). 
Of the 21 cases, 7 were composed exclusively of spindle
cells that were arranged in long fascicles and resembled either
leiomyosarcoma or fibrosarcoma. Eight cases consisted of pleo-
morphic cells with abundant cytoplasm and multinucleated
giant cells. Six cases contained a mixture of spindle cells and
giant cells. Of 6 cases with only sarcomatous components, 3
showed pure spindle cell elements, and 3 demonstrated a mix-
ture of two sarcomatous components. Because of the morpho-
logic difference between spindle cells and giant cells in PLC,
it was speculated that the expression patterns of various pro-
teins on these cells might differ and be correlated with the
clinicopathological characteristics of PCL. Thus, we examined
Case Age (yr)
Sarcomatous
component (%)
Sarcomatous
component
Epithelial 
component
Patients
status Sex Stage Site
1 50 M LUL 20 spindle cells large IIA dead
2 61 M LLL 50 giant cells large IIB dead
3 66 M RUL 100 mixed none IIB dead
4 75 M LLL 40 giant cells large IIIA dead
5 58 M RLL 40 spindle cells adeno IIIB dead
6 91 M LUL 100 mixed none IIB dead
7 82 M LUL 100 giant cells none IIIA alive
8 62 M LUL 40 spindle cells large IIB missing
9 60 M LUL 40 spindle cells squamous IIB missing
10 57 M RUL 80 spindle cells adeno IIA dead
11 73 M LLL 90 mixed large IIIB dead
12 59 M RUL 50 mixed adeno IIIA alive
13 79 F LUL 80 giant cells large IIIB missing
14 65 M RUL 60 spindle cells squamous IIA dead
15 59 M RUL 100 giant cells none IIB alive
16 77 M RUL 100 giant cells none IIB alive
17 64 M LUL 40 giant cells large IIIA alive
18 72 M LUL 100 mixed none IIIA dead
19 55 M RML 20 giant cells large IIIA dead
20 58 M LUL 30 spindle cells squamous IIB alive
21 51 M RUL 70 mixed adeno IIB dead
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the expression pattern of CD99 on the spindle and giant cells
of PLC, respectively. 
The immunohistochemistry result of the present study are
summarized in Table 2. In 15 cases containing carcinomas,
all carcinomatous components were immunoreactive for cyto-
keratin 7, and epithelial membrane antigen (EMA), whereas
cytokeratin 20 was not expressed on any carcinomatous or
sarcomatous component. The sarcomatous components of all
21 cases were positive for vimentin. Of 13 cases containing
spindle cells, CK7 was expressed on spindle cells in 6 cases
(43%), TTF-1 in 2 (15%), and CD99 in 11 (85%). Of 14
cases containing giant cells as a sarcomatous component, six
cases (57%) were immunoreactive for CK7, 2 (14%) for TTF-
1, and 9 (64%) for CD99. TTF-1 was expressed in 5 of 15
cases containing a carcinomatous component, 3 of which were
adenocarcinomas and 2 were large cell carcinomas. However,
the components of squamous cell carcinoma in three PLCs
were negative for TTF-1.
The expression of CD99 in carcinoma was observed in 7 of
15 PCLs. These were as large cell carcinomas in 3 cases, ade-
nocarcinomas in 2, and squamous cell carcinoma in 2 (Fig.
2A). Immnoreactivity for CD99 in sarcomatoid components
Fig. 1. (A) Spindle cells of sarmocomatous areas whirled around carcinomatous component (H&E, ×200). (B) Giant cells are admixed with
spindle cell components (H&E, ×200). (C) Spindle cells show immunoreactivity for cytokeratin 7 (×400). (D) TTF-1 nuclear stainings are
detected in spindle cells in sarcomatous area (×400).
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was intense and diffuse on the cell membrane (Fig. 2B-D). The
expression patterns of TTF-1 and CD99 were not statistically
related to clinical or pathological parameters, such as histo-
logical subtype and staging of PCL. 
DISCUSSION
The CD99 protein is ubiquitously expressed in a variety of
human normal tissues and malignant cells (21-24). In normal
tissue CD99 is highly expressed in cortical thymocytes, pan-
creatic islet cells, granulosa cells of the ovary, Sertoli’s cells and
ependymal cells. It is also expressed on fibroblasts, endothe-
lial cells, smooth muscle cells and respiratory epithelial cells
in which the level of expression is relatively low (24, 25). Even
though CD99 is known to be a specific marker for Ewing/
PNET, it is expressed in a variety of tumors (20-22, 24-26).
With respect to neoplasms of the lung, CD99 is expressed
in 25% of pulmonary neuroendocrine tumors and is preferen-
tially confined to typical carcinoids (19). It is generally accept-
ed that CD99 is not a specific marker for a particular subset
of neoplasms. The present study demonstrates that CD99
expression is not only shown by spindle cells and giant cells
in PCL, rather all cases containing a carcinomatous compo-
Fig. 2. (A) Carcinoma component of PCL showing CD99 surface expression on tumor cells (×200). (B, C) CD99 immunoreacitivity was
detected on spindle cells (B: ×200, C: ×400). (D) CD99 is observed on giant cells (×400).
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nent showed various degrees of CD 99 positivity. In terms
of sarcomatous component, the percentage of CD99-positive
cells was higher in spindle cells than in giant cells. Our results
support the concept that CD99/MIC-2 is not a specific marker
for distinguishing a particular subset of human tumors. More-
over, it has been reported that CD99 plays critical role in the
invasion, motility, and proliferation of malignant cells (27-
33). Pelosi et al. reported a statistically significant relation-
ship between the number of CD99 positive cells and the pres-
ence of local invasion and/or distant metastasis, and the Ki-
67 index in gastrointestinal and pulmonary neuroendocrine
tumors (19). These findings suggest that CD99 may be in-
volved in cell-to-cell adhesion of neuroendocrine tumor cells
and in downregulation of their proliferative activity. Thus, to
explore the biological implication of CD99 in PCL we ana-
lyzed patient clinico-pathologic data. However, CD99 expres-
sion in PCL was not found to be correlated with patient prog-
nostic parameters. These findings suggest that the expression
of CD99 in PCL does not contribute to the anti-proliferation
PCL tumor cells.
Although the histogenesis of PCL has not been clearly ex-
plored, several groups have suggested the possibility that PCL
is a carcinoma with divergent sarcomatous differentiation,
rather than being a collision neoplasm. Recently Rossi et al.
studied 58 cases of PCL that showed immunoreactivity for
CK7 and TTF-1 in the epithelial and sarcomatous elements
(34). In addition, three groups have demonstrated that the
epithelial and sarcomatous components of PCL show the same
genetic abnormalities by microdissection analysis (35-37).
These findings support the concept that the sarcomatous com-
ponents of PCL might be derived from epithelial components.
Like CK7, CD99 was also expressed on spindle and/or giant
cells as well as PCL carcinomas in the present study. However,
these findings inadequately support the concept that spindle
and giant cells are derived from carcinoma because CD99 is
more widely expressed on human mesenchymal components
and sarcomas than carcinomas. Thus, it is more likely that
the expression of CD99 on sarcomatous component of PLC
reflects tumor cell mesenchymal differentiation status.
In summary, CD 99 was found to be widely expressed in
both sarcomatoid and epithelial components in PCL, like other
epithelial markers. Although the biological implications of its
expression in PCL remain unclear, the clinicopathological anal-
ysis demonstrated no direct correlation between the expres-
sions of CD99 in PCL and the clinical indices of PCL patients.
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